Results 141 to 150 of about 1,388,675 (309)

Guidelines for the evaluation of drug prevention: a manual for programme planners and evaluators.

, 2012
he EMCDDA first published the Guidelines for the evaluation of drug prevention in 1998 to respond to a need expressed by professionals and policymakers to have a tool and stimulus to evaluate prevention interventions in Europe.

core  

An exhaustive examination of the research progress in identifying potential JAK inhibitors from natural products: a comprehensive overview

Chinese Medicine
The JAK-STAT signaling pathway serves as a central regulator of diverse cellular processes encompassing proliferation, apoptosis, inflammation, and differentiation.
Wendong Yang, Jiabin Lu, Peihua Luo, Zhifei Xu, Hao Yan, Bo Yang, Qiaojun He, Jialin Zhou, Xiaochun Yang   +8 more
doaj   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

Advanced lung organoids and lung-on-a-chip for cancer research and drug evaluation: a review. [PDF]

Front Bioeng Biotechnol, 2023
Zhu L, Zhang J, Guo Q, Kuang J, Li D, Wu M, Mo Y, Zhang T, Gao X, Tan J.   +9 more
europepmc   +1 more source

The Evaluation of New Drugs

Journal of Pharmacy and Pharmacology, 1958
L G, GOODWIN, F L, ROSE
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Value-Based Generic Drug Evaluation Focus on Chinese Real-World Evidence. [PDF]

Int J Health Policy Manag, 2023
Lu J, Ying X, Li Z.
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Evaluation of drug prevention activities: theory and practice.

, 2010
This publication will explore the limitations for evaluation of drug prevention interventions and address the ways that evaluation can be made more effective.
Ives, Richard, Uhl, Alfred
core  

Human skin-on-a-chip for mpox pathogenesis studies and preclinical drug evaluation. [PDF]

Trends Pharmacol Sci, 2023
Zhu J, Abaci HE.
europepmc   +1 more source